📢 Thrilled to share one of our recent contributions to the scientific community! 🧠 Our review article, “Central Post-Stroke Pain: Advances in Clinical and Preclinical Research”, was published in Stroke & Vascular Neurology.
This comprehensive review explores the clinical characteristics, evaluation methods, and therapeutic strategies for central post-stroke pain (CPSP). It bridges the gap between clinical findings and preclinical models, offering insights into the condition’s mechanisms and future directions for treatment development.
It’s a privilege to collaborate with such talented researchers, and I hope this work can guide further advancements in understanding and managing CPSP.
CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication of foundational findings in the Annals of Clinical and Translational Neurology. The study highlights neuromuscular junction (NMJ) dysfunction as a characteristic in Charcot-Marie-Tooth disease (CMT) types 1 and 2, identifying its impact on muscle function and disease severity. This research laid the groundwork for NMD Pharma’s SYNAPSE-CMT Phase II clinical trial, which is now actively recruiting participants.
Learn more: https://lnkd.in/eeKh74kw#CMTResearch#CMTASTAR#CharcotMarieTooth#CMTDisease#LetsBeatCMT#CMTAFamily
Northwestern and members of the ALS community gathered to celebrate progress and share research at the 14th annual Les Turner Symposium on ALS: http://spr.ly/6049svszL
The daylong symposium featured sessions highlighting new research on amyotrophic lateral sclerosis, or ALS, a progressive neurodegenerative disease that deteriorates motor neurons in the brain and spinal cord, causing muscle weakness.
The Ken & Ruth Davee Department of Neurology at Northwestern University
Discover the Future of CNS Therapeutics: The Promise of KCC2 Activation
Join us on November 13 as we explore a breakthrough in neuroscience, focusing on a critical target in the central nervous system (CNS) – KCC2. This unique transporter, found exclusively in the brain, plays a fundamental role in controlling neuron excitability. Activating KCC2 holds transformative potential for treating a wide spectrum of neurological conditions by addressing the underlying mechanisms that drive disorders such as epilepsy, psychosis, and mood disorders.
Ovid Therapeutics is at the forefront of advancing this field. We are proud to have developed multiple KCC2 activators and are on track to submit our first IND for OV350, a promising candidate that could open doors to life-changing therapies for those affected by CNS diseases.
I’ll be joined by esteemed experts, Professors Stephen Moss, Jeffrey Noebels, and Karl Kieburtz, along with key leaders from Ovid, to discuss the groundbreaking science behind KCC2 activation. Together, we’ll delve into how this new approach could reshape treatment paradigms for brain disorders.
Don’t miss this chance to engage with a new frontier in small molecule neurotherapeutics and witness the potential impact of KCC2 on the future of brain health.
Save the Date: November 13
Be part of the conversation that could redefine the future of CNS treatments.
Register to join in person: https://lnkd.in/dvZvmvCc
Register to join the virtual webcast: https://lnkd.in/dWJfKxkV
We’re honored to welcome three recognized thought leaders in neurology and neuropharmacology to present at Ovid’s KCC2 Download Day next week.
Stephen Moss, Jeff Noebels and Karl Kieburtz will discuss the biological functions, underlying mechanisms and therapeutic promise of directly activating KCC2. KCC2 is one of the most exciting novel pathways in neurology due to its role in modulating neuronal hyperexcitability and neuroinflammation, the root cause of many brain disorders.
Join us on November 13 to explore the biological and therapeutic significance of KCC2 activation across a wide range of CNS conditions.
Register to join in person: https://lnkd.in/eGzQqw9X
Register to join the virtual webcast: https://lnkd.in/eCBq8gFC
Hello connections,
I am excited to share my review article on "Targeting Adipokines: A Promising Therapeutic Strategy for Epilepsy," published in the journal "Neurochemical Research" with an impact factor of 4.2.
As we continue to explore innovative approaches in neurology, understanding the role of adipokines could pave the way for more effective treatments in epilepsy. The role of adipokines in the CNS is multifaceted and plays a significant part in various physiological and pathological processes. This review aims to highlight the potential impacts of leptin, apelin, adiponectin, vaspin, visfatin and chimerin in the pathogenesis of epilepsy.
https://lnkd.in/dvJxKrFi
I want to extend my heartfelt gratitude to
my guide Lokesh Bhatt sir, for his invaluable guidance and support throughout this journey. I am grateful to SVKM's BNCP for providing a nurturing environment that fosters research and innovation. I would also like to acknowledge the reviewers and editors for their valuable feedback.
#research#epilepsy#insights
Multicenter Study Neurology. 2013 Dec 3;81(23):2024-7. doi: 10.1212/01.wnl.0000436935.47657.78. Epub 2013 Nov 13.
Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. DOI:10.1212/01.wnl.0000436935.47657.78
It is the way, to determine potencially the risk factor for the impact of cerebral microcirculatory flow and remodeling and development on a genetic basis conducive to Alzheimer's type and or mixed
We are pleased to share the publication “Choroid plexus tumors in adults: a retrospective mono-institutional study” in Neurological Sciences, the official journal of the Italian Society of Neurology (SIN), authored by Dra. Ludmila Koch, Chair of the LACOG Geriatric Group, and other authors.
This retrospective observational study collected clinical and radiological data from 24 consecutive patients diagnosed with CPT (choroid plexus tumors). The study confirmed that CPT can occur in adults and are mostly grade 1 tumors located in the ventricular system.
Read the full article in Neurological Sciences: https://lnkd.in/dEhJ7b_H#LACOG#CancerResearch
Advancing brain health with precision. At Synthesys Brain Health, our collaboration between Lifelines Neuro and Neurovative Diagnostics ensures top-tier EEG data and services, supporting CNS drug development trials. Dive deeper into how we're shaping the future of neurology, one trial at a time. Learn more about our clinical trials ➡ synthesyshealth.com
Join Anna Krause and Magdalena Tyszkiewicz (Woźnica) during XXV Congress of the Polish Society of Neurology, which starts on September 11th in Bialystok.
Pikralida is developing a novel treatment for ischemic stroke, a condition that continues to pose significant challenges in neurology. Pikralida is working toward initiating the phase 2 Proof-of-Concept clinical trial focused on evaluating the neuroprotective potential of the drug candidate PKL-021 in reducing brain tissue damage, minimizing stroke consequences resulting in the acceleration of the recovery process, and preventing epilepsy development in the patient.
Learn more about the event: https://lnkd.in/dZsD7S4a#neuroprotection#stroketreatment#drugdevelopment#Pikralida
🔬Live videos from our neurology labs shows some of the exciting experiments that our research teams are conducting on a daily basis.
In this experiment, InnoSer scientists have compared the neuromuscular function of healthy (WT) and diseased research subjects (C3-PMP22 research model of Charcot Marie Tooth Disease Type 1A, #CMT1A). Briefly, the hindlimbs of the research models have been stimulated and compound muscle action potentials (#CMAPs) recorded, showing significant changes in CMAP compared to healthy subjects. Calculation of latency and CMAP annotation are performed manually by our scientists to ensure accurate results. All in all, this confirms that this research model of CMT1A has significantly impaired neuromuscular function, confirming its suitability as a preclinical research model for efficacy testing of novel CMT1A targeted treatments.
👉 Read more about the C3-PMP22 model of #CMT1A here: https://lnkd.in/eSEm96Z4
👉 Interested in using the C3-PMP22 mouse model for your research? Don’t hesitate to contact us for more information here: https://lnkd.in/eHH4bmZT#SeeCMT#NavigatingCMT#NeuroscienceResearch#NeurologyCRO#NeuroscienceCRO#EuropeanNeurologyCRO#CharcotMarieToothDisease
Bsc in pharmacy, master position candidate, article writer
3moWell done congrats👍